Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Mallinckrodt
Moodys
Baxter
Colorcon
Queensland Health
Cantor Fitzgerald
AstraZeneca
QuintilesIMS
Deloitte

Generated: May 21, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 022239

« Back to Dashboard

NDA 022239 describes SUMAVEL DOSEPRO, which is a drug marketed by Endo Ventures Ltd and is included in one NDA. It is available from two suppliers. There are nine patents protecting this drug. Additional details are available on the SUMAVEL DOSEPRO profile page.

The generic ingredient in SUMAVEL DOSEPRO is sumatriptan succinate. There are twenty-four drug master file entries for this compound. Forty-five suppliers are listed for this compound. Additional details are available on the sumatriptan succinate profile page.
Summary for 022239
Tradename:SUMAVEL DOSEPRO
Applicant:Endo Ventures Ltd
Ingredient:sumatriptan succinate
Patents:9
Formulation / Manufacturing:see details
Pharmacology for NDA: 022239
Suppliers and Packaging for NDA: 022239
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
SUMAVEL DOSEPRO sumatriptan succinate INJECTABLE;SUBCUTANEOUS 022239 NDA Zogenix, Inc. 43376-104 E 43376-104-01
SUMAVEL DOSEPRO sumatriptan succinate INJECTABLE;SUBCUTANEOUS 022239 NDA Zogenix, Inc. 43376-104 E 43376-104-06

Profile for product number 001

Active Rx/OTC/Discontinued:DISCNDosage:INJECTABLE;SUBCUTANEOUSStrengthEQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)
Approval Date:Jul 15, 2009TE:RLD:Yes
Patent:➤ Try a Free TrialPatent Expiration:Nov 22, 2026Product Flag?YSubstance Flag?Delist Request?
Patent:➤ Try a Free TrialPatent Expiration:Jul 31, 2026Product Flag?YSubstance Flag?Delist Request?
Patent:➤ Try a Free TrialPatent Expiration:Aug 10, 2023Product Flag?YSubstance Flag?Delist Request?

Expired US Patents for NDA 022239

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Endo Ventures Ltd SUMAVEL DOSEPRO sumatriptan succinate INJECTABLE;SUBCUTANEOUS 022239-001 Jul 15, 2009 ➤ Try a Free Trial ➤ Try a Free Trial
Endo Ventures Ltd SUMAVEL DOSEPRO sumatriptan succinate INJECTABLE;SUBCUTANEOUS 022239-001 Jul 15, 2009 ➤ Try a Free Trial ➤ Try a Free Trial
Endo Ventures Ltd SUMAVEL DOSEPRO sumatriptan succinate INJECTABLE;SUBCUTANEOUS 022239-001 Jul 15, 2009 ➤ Try a Free Trial ➤ Try a Free Trial
Endo Ventures Ltd SUMAVEL DOSEPRO sumatriptan succinate INJECTABLE;SUBCUTANEOUS 022239-001 Jul 15, 2009 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Citi
Covington
Deloitte
Fish and Richardson
Mallinckrodt
Farmers Insurance
Julphar
Cantor Fitzgerald
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.